Raphael Pharmaceutical Appoints New Auditor
Ticker: RAPH · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1415397
| Field | Detail |
|---|---|
| Company | Raphael Pharmaceutical Inc. (RAPH) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Raphael Pharma switches auditors from BDO to Marcum, effective Sept 5th. No disagreements cited.
AI Summary
Raphael Pharmaceutical Inc. announced on September 11, 2024, that it has appointed a new independent registered public accounting firm, Marcum LLP, effective September 5, 2024. This change follows the resignation of the company's former auditor, BDO USA, P.A. The company stated that the decision to change auditors was not a result of any disagreements with BDO USA, P.A.
Why It Matters
Changing auditors can sometimes signal underlying issues or a strategic shift within a company, potentially impacting investor confidence and future financial reporting.
Risk Assessment
Risk Level: medium — A change in auditors, especially without explicit reasons beyond routine, can sometimes precede or coincide with other significant events or financial scrutiny.
Key Players & Entities
- Raphael Pharmaceutical Inc. (company) — Registrant
- Marcum LLP (company) — New independent registered public accounting firm
- BDO USA, P.A. (company) — Former independent registered public accounting firm
- September 11, 2024 (date) — Date of report
- September 5, 2024 (date) — Effective date of auditor change
FAQ
Who is Raphael Pharmaceutical Inc.'s new independent registered public accounting firm?
Raphael Pharmaceutical Inc. has appointed Marcum LLP as its new independent registered public accounting firm.
When was the change in auditors effective?
The change in auditors was effective as of September 5, 2024.
Who was Raphael Pharmaceutical Inc.'s previous auditor?
Raphael Pharmaceutical Inc.'s previous auditor was BDO USA, P.A.
Were there any disagreements between Raphael Pharmaceutical Inc. and its former auditor, BDO USA, P.A.?
The filing states that the decision to change auditors was not the result of any disagreements between Raphael Pharmaceutical Inc. and BDO USA, P.A.
What is the filing date of this 8-K report?
This 8-K report was filed on September 11, 2024.
Filing Stats: 937 words · 4 min read · ~3 pages · Grade level 16.1 · Accepted 2024-09-11 16:01:33
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share Indicate by check mark whet
Filing Documents
- ea0214273-8k_raphael.htm (8-K) — 32KB
- ea021427301ex16-1_raphael.htm (EX-16.1) — 7KB
- ex16-1_001.jpg (GRAPHIC) — 10KB
- ex16-1_002.jpg (GRAPHIC) — 24KB
- 0001213900-24-077706.txt ( ) — 253KB
- raph-20240905.xsd (EX-101.SCH) — 3KB
- raph-20240905_lab.xml (EX-101.LAB) — 33KB
- raph-20240905_pre.xml (EX-101.PRE) — 22KB
- ea0214273-8k_raphael_htm.xml (XML) — 3KB
01. Changes in Registrant's Certifying Accountant
Item 4.01. Changes in Registrant's Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm On September 11, 2024, the Board of Directors of Raphael Pharmaceutical Inc., or the Company, dismissed Weinstein International CPA, or the Former Auditor, as the Company's independent registered public accounting firm, effective September 5, 2024. Except for an explanatory paragraph in the Former Auditor's audit report regarding substantial doubt about the Company's ability to continue as a going concern, the audit reports of the Former Auditor on the Company's financial statements for the fiscal years ended December 31, 2022 and 2023 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the fiscal years ended December 31, 2022 and 2023, and the subsequent interim period through September 5, 2024, there were (i) no "disagreements" (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and the Former Auditor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the Former Auditor, would have caused the Former Auditor to make reference to the subject matter of the disagreement in its reports on the Company's financial statements and (ii) no "reportable events" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions). The Company provided the Former Auditor with a copy of the disclosures it is making in this Current Report on Form 8-K and requested that the Former Auditor furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made herein and, if not, stating the respects in which it does not agree. A copy of the letter provided by the Former Aud
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 16.1 Letter from Weinstein International CPA, addressed to the Securities and Exchange Commission, dated September 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPHAEL PHARMACEUTICAL INC. By: /s/ Shlomo Pilo Name: Shlomo Pilo Title: Chief Executive Officer Date: September 11, 2024 2